US 11,987,617 B2
Antibodies that target HIV GP120 and methods of use
Mini Balakrishnan, San Mateo, CA (US); Brian A. Carr, Foster City, CA (US); Magdeleine S. Hung, Mountain View, CA (US); Manu Kanwar, San Marcos, CA (US); Doug Rehder, Bonsall, CA (US); Matthew Robert Schenauer, Dana Point, CA (US); Loredana Serafini, Orinda, CA (US); and Nathan D. Thomsen, Castro Valley, CA (US)
Assigned to GILEAD SCIENCES, INC., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Aug. 4, 2023, as Appl. No. 18/365,869.
Application 17/496,250 is a division of application No. 16/460,094, filed on Jul. 2, 2019, granted, now 11,168,130, issued on Nov. 9, 2021.
Application 18/365,869 is a continuation of application No. 17/496,250, filed on Oct. 7, 2021.
Claims priority of provisional application 62/810,191, filed on Feb. 25, 2019.
Claims priority of provisional application 62/693,642, filed on Jul. 3, 2018.
Prior Publication US 2024/0034774 A1, Feb. 1, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/42 (2006.01); A61P 31/18 (2006.01); C07K 16/10 (2006.01); A61K 45/06 (2006.01)
CPC C07K 16/1063 (2013.01) [A61P 31/18 (2018.01); A61K 45/06 (2013.01); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2317/76 (2013.01)] 21 Claims
OG exemplary drawing
 
1. An antibody or an antigen-binding fragment thereof that binds to human immunodeficiency virus-1 (HIV-1) Envelope glycoprotein gp120, the antibody or antigen-binding fragment thereof comprising (i) a heavy chain variable region (VH) comprising VH complementary determining regions 1-3 (CDRs 1-3) and (ii) a light chain variable region (VL) comprising VL CDRs 1-3, wherein the VH CDRs 1-3 and VL CDRs 1-3 have the sequences set forth in: SEQ ID NOs.: 137, 138, 139, 140, 141, and 142, respectively, and wherein at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or more, N-linked glycosylation sites in the VL are sialylated.